Traders should base analysis on the underlying index (XBI), as LABU's price action is distorted by leverage-induced drift.

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. This ETF attempts to mimic 3X the ...

First, the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) seeks daily investment results, before fees and expenses, of 300% of the performance of the aforementioned biotech index. Second, the ...

Thanks to some favorable news from the Food and Drug Administration (FDA) and more mergers and acquisitions activity, biotechnology stocks and exchange traded are shaking off their previously ...

Seeking Alpha Quant rates LABU as a strong Sell, but I rates it as a Buy due to bullish market conditions. LABU is a leveraged ETF that seeks to track 3x the daily performance of the S&P Biotechnology ...

Payable Dec 31; for shareholders of record Dec 23; ex-div Dec 23. More on Direxion Daily S&P Biotech Bull 3X Shares LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF Seeking Alpha’s Quant ...

Investors in Direxion Shares Exchange Traded Fund Trust - Direxion Daily S&P Biotech Bull 3X Shares (Symbol: LABU) saw new options become available today, for the June 2nd expiration. At Stock Options ...

Sean Ross is a strategic adviser at 1031x.com, Investopedia contributor, and the founder and manager of Free Lances Ltd. The Direxion Daily S&P Biotech Bull 3X Fund (NYSEARCA: LABU) is an exchange ...

Over the past 12 months, LABU has changed by 84.38%, with its 52-week range spanning from 32.55 to 179.14. What Is the Daily Trading Range for LABU? The daily trading range for LABU has fluctuated ...

Biotechnology stocks and the related exchange traded funds are off to sizzling starts in 2019. Really, really sizzling. With the group off to its best start to a year since 2012, the S&P Biotechnology ...

Steven Nickolas is a writer and has 10+ years of experience working as a consultant to retail and institutional investors. Suzanne is a content marketer, writer, and fact-checker. She holds a Bachelor ...